ABIVAX Signs Agreement with the Finlay Institute to Commercialise Meningococcal and Typhoid Vaccines in Asia and Latin America

November 12, 2014 ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets. Under the terms of the agreement, ABIVAX will gain exclusive …

PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

July 28th, 2014 PaxVax Inc. a specialty vaccine company focused on travel and biodefense today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG as well as its manufacturing facility in Thörishaus near Bern Switzerland. Additionally PaxVax is acquiring marketing sales and distribution capabilities in select markets including the United States and certain other assets …

Novartis teams with India’s Biological E for typhoid vaccine development

Novartis and Indian biopharma Biological E have entered into a development and licensing agreement  to deliver accessible and affordable typhoid and paratyphoid A vaccines to the developing world. Yearly, over 21 million cases and 5 million cases of typhoid and paratyphoid A fever respectively are reported, with many typhoid victims being children younger than two for which there is no …